Shield Therapeutics (Shield) is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Following the US launch of Accrufer® in July 2021, the initial challenge was to greatly improve market awareness of its differentiating features as an oral ID drug. The US market offers enormous potential, but it takes time to get new drugs on to formularies and sales traction. The market was disappointed by initial sales reported in a recent trading update. However, even on revised forecasts, Shield is expected to become profitable and cash-generative in 2023.
If you'd like to be introduced to the team at Shield Therapeutics Plc, get in touch.Request a meeting